0.2876
price up icon13.14%   0.035
after-market Handel nachbörslich: .28 -0.0076 -2.64%
loading
Schlusskurs vom Vortag:
$0.2526
Offen:
$0.254
24-Stunden-Volumen:
1.08M
Relative Volume:
0.06
Marktkapitalisierung:
$18.00M
Einnahmen:
$1.16M
Nettoeinkommen (Verlust:
$-37.28M
KGV:
-0.4959
EPS:
-0.58
Netto-Cashflow:
$-33.81M
1W Leistung:
+5.93%
1M Leistung:
+14.92%
6M Leistung:
+31.10%
1J Leistung:
-91.59%
1-Tages-Spanne:
Value
$0.254
$0.2899
1-Wochen-Bereich:
Value
$0.2426
$0.2899
52-Wochen-Spanne:
Value
$0.1406
$3.47

Glycomimetics Inc Stock (GLYC) Company Profile

Name
Firmenname
Glycomimetics Inc
Name
Telefon
240-243-1201
Name
Adresse
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
35
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
GLYC's Discussions on Twitter

Vergleichen Sie GLYC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GLYC
Glycomimetics Inc
0.2876 18.00M 1.16M -37.28M -33.81M -0.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-26 Herabstufung TD Cowen Buy → Hold
2023-12-22 Eingeleitet CapitalOne Overweight
2021-11-12 Hochstufung Jefferies Hold → Buy
2019-11-14 Eingeleitet ROTH Capital Buy
2019-08-05 Herabstufung Jefferies Buy → Hold
2019-08-05 Herabstufung Piper Jaffray Overweight → Neutral
2019-08-05 Herabstufung SunTrust Buy → Hold
2019-04-12 Eingeleitet Piper Jaffray Overweight
2018-12-18 Eingeleitet H.C. Wainwright Buy
2016-07-26 Eingeleitet SunTrust Buy
2015-03-17 Bestätigt Stifel Buy
Alle ansehen

Glycomimetics Inc Aktie (GLYC) Neueste Nachrichten

pulisher
Jan 25, 2025

GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World

Jan 25, 2025
pulisher
Jan 20, 2025

Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World

Jan 17, 2025
pulisher
Jan 15, 2025

GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.

Jan 13, 2025
pulisher
Jan 09, 2025

StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World

Jan 09, 2025
pulisher
Jan 01, 2025

GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 01, 2025
pulisher
Dec 30, 2024

Is It Time For Me To Buy GlycoMimetics Inc (NASDAQ: GLYC) Stock Now? - Stocks Register

Dec 30, 2024
pulisher
Dec 27, 2024

GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World

Dec 27, 2024
pulisher
Dec 19, 2024

GlycoMimetics, Inc. announced that it expects to receive $200 million in funding - Marketscreener.com

Dec 19, 2024
pulisher
Dec 16, 2024

GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World

Dec 16, 2024
pulisher
Dec 02, 2024

GlycoMimetics skyrockets on buyout deal - MSN

Dec 02, 2024
pulisher
Nov 27, 2024

Logos Global Management LP Acquires 5 Million Shares in GlycoMim - GuruFocus.com

Nov 27, 2024
pulisher
Nov 24, 2024

StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World

Nov 24, 2024
pulisher
Nov 14, 2024

GlycoMimetics: Q3 Earnings Snapshot - Darien Times

Nov 14, 2024
pulisher
Nov 12, 2024

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Quantisnow

Nov 12, 2024
pulisher
Nov 12, 2024

Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - StockTitan

Nov 12, 2024
pulisher
Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve

Nov 09, 2024
pulisher
Nov 08, 2024

Finansavisen - Finansavisen

Nov 08, 2024
pulisher
Nov 07, 2024

RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace

Nov 06, 2024
pulisher
Nov 06, 2024

Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News

Nov 06, 2024
pulisher
Nov 06, 2024

Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC - WICZ

Nov 05, 2024
pulisher
Nov 05, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register

Nov 05, 2024
pulisher
Nov 03, 2024

INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire

Nov 03, 2024
pulisher
Nov 01, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve

Nov 01, 2024
pulisher
Nov 01, 2024

GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle

Nov 01, 2024
pulisher
Oct 31, 2024

GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

3 Penny Stocks to Watch Now, 10/31/24 - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

GlycoMimetics To Acquire Crescent Biopharma - FinSMEs

Oct 30, 2024
pulisher
Oct 30, 2024

Kuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law Firm - Morningstar

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St

Oct 30, 2024
pulisher
Oct 30, 2024

Biotech Up Over +100% Premarket Following Merger And Funding Announcement - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com

Oct 29, 2024

Finanzdaten der Glycomimetics Inc-Aktie (GLYC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$352.30
price down icon 5.46%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 2.77%
biotechnology ONC
$226.89
price up icon 0.17%
$120.88
price down icon 0.23%
Kapitalisierung:     |  Volumen (24h):